RVMD Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Zacks Investment Research - Mentions: ALKS ANIP CRMD

Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil

10 days ago - By: The Motley Fool

Revolution Medicines (RVMD) Earnings Transcript

10 days ago - By: Revolution Medicines, Inc.

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

11 days ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

17 days ago - By: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

24 days ago - By: Benzinga - Mentions: TNGX

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

24 days ago - By: Revolution Medicines, Inc.

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

a month ago - By: Investor's Business Daily - Mentions: RY RY.CA IRON ACHV ...

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

a month ago - By: Stocktwits - Mentions: IRON REGN SNY LLY ...

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

a month ago - By: Revolution Medicines, Inc.

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

2 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

2 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

3 months ago - By: Yahoo Finance - Mentions: RPRX GILD

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

3 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

4 months ago - By: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

4 months ago - By: Revolution Medicines, Inc.

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

4 months ago - By: Yahoo Finance - Mentions: GS

Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs

4 months ago - By: Revolution Medicines, Inc.

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

5 months ago - By: Yahoo Finance - Mentions: PRMB

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress

5 months ago - By: Yahoo Finance - Mentions: PRMB

Primo Brands Stock Backed by Barclays on Hydration Market Strength

5 months ago - By: Summit Therapeutics Inc. - Mentions: SMMT

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

5 months ago - By: Revolution Medicines, Inc.

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

5 months ago - By: Stocktwits - Mentions: RPRX VTI

REVOLUTION MEDICINES INC (RVMD) Stock News

RVMD Latest News, Press Relases and Analysis

Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil

Revolution Medicines (RVMD) Earnings Transcript

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Earnings Scheduled For November 5, 2025

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress

Primo Brands Stock Backed by Barclays on Hydration Market Strength

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma